Amgen wins US patent for Enbrel
The entitled patent owned by Hoffman-La Roche’s (Roche) was licensed to Amgen upon a one-time payment and received an exclusive, fully paid-up license to the application which issued
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.
The development of therapeutic will make use of Intrexon’s UltraVector platform and RheoSwitch Therapeutic System. Adeona will utilize Intrexon’s transgene engineering platform for the controlled, precise and continuous
Revlimid is used to treat patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. Patients with MDS develop severe